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In the inhibition of specific binding of [~:Sl]endothelins (ETs) to membranes from various tissues of rats, guinea pigs, pigs and humans, [Cys ~'- 
Cyst~]-ET-l( I 1-21 ), IRL 1038, has a much higher affinity for ETa receptors (Ki - 6-11 nM) than for ET,., receptors (Ka = 0.4-0.7,a M). In contraction 
a.~ays, with ET-3 as a stimulant, 3 ,aM IRL 1038 antagonized the ET~ receptor-mediated contraction of guinea pig ileal and tracheal smooth muscle 
without any significant agonistie activity, but did not effect the ETA receptor-mediated contraction of rat aortic smooth muscle. IRL 1038 is, 
therefore, considered to be the first antagonist elective to the ETn receptor. 
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1. INTRODUCTION 
Endothelin (ET) was discovered as a potent vasoac- 
tive peptide produced by cultured endothelial cells [1]. 
The peptide, now known as ET-1, is a member of a 
family of three distinct isopeptides, ET-1, ET-2, and 
ET-3 [2]. Sarafotoxins, isolated from the venom of the 
snake, Atractaspis engaddensis, also possess tructural 
features and pharmacological ctivities imilar to those 
of ETs [3]. ETs and sarafotoxins exert various pharma- 
cological actions, such as transient vasodilation and 
prolonged contraction of bronchial, intestinal and uter- 
ine smooth muscle (see [4] for review). These pharma- 
cological actions are mediated by two distinct subtypes 
of ET receptor, i.e. the ET^ receptor (ET-1- and ET-2- 
selective) and the ETa receptor (ET isopeptide non- 
selective) (see [5] for review). However, a distinction 
between ETA- and ETa-mediated functions till remains 
unestablished, mainly because of the lack of antagonists 
specific for each subtype of the receptor. Several specific 
,-antagonists for the ETA receptor have recently been 
isolated from Streptomyces f rmentation products [6,7] 
and bayberry extracts [8] and prepared by chemical 
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modification of ET- 1 [9], but no antagonists selective to 
the ETa receptor have as yet been reported. 
In an attempt o develop specific antagonists for the 
ETa receptor, we noticed the fact that this receptor 
recognizes the structure common to all the three ET 
isopeptides. We therefore synthesized a peptide corre- 
sponding to the C-terminal half (residues 11-21) of ET- 
1, because this segment is conserved in all the three ET 
isopeptides. The structure of the peptide thus synthe- 
sized (called IRL 1038) is: [Cys It-CysJS]-ET-l(l 1-21). It 
has a Cys ~ ~-Cys ~ disulfide bond instead of the two di- 
sulfide bonds at CysJ-Cys Ls and Cys~-Cys t~ in ETs. Here 
we report that IRL 1038 is in t:act a specific antagonist 
for the ETa receptor. By using this antagonist, we also 
show that contraction of guinea pig ileal and tracheal 
smooth muscle is, at least in part, mediated by the ETa 
receptor. 
2. MATERIALS AND METHODS 
2.1. Materials" 
[12~IIET-I and [t-'Si]ET-3 (-74 TBq/mmol)were purchased from 
Amerslaam (Buckinghamshire, UK). Authentic ET-I and ET-3 (Pep. 
tide Institute Inc., Osaka, Japan), protected amino acids, reagents for 
peptide synthesis (Applied 8iosystems, Foster City, CA), and disuc- 
einimidyl suberate (DSS) (Pierce Chemical. Rockford, IL) were oh. 
rained commercially. All other chemicals used were of reagent grade. 
2.2. Peptid¢ #),nthesis 
IRL 1038 (~ys-Val-:fyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp) was syn. 
tbesized by a solid-phase procedure on an Applied Biosystems Model 
431A automated peptide synthesizer. The peptide was constructed on 
0.5 mmol of Boc-Trpi.CHO)-phenylacetoumidomethyl resin and elon- 
gated by in situ prepared l-hydroaybcnzotriazolc esters usin~ a 4-fold 
excess of Boo-amino acid d~rivatives. The completed peptide resin was 
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treated with hydrogen fluoride in the presence of anisole and 1,2- 
ethanedithiol t  remove all the protecting groups and the resin. The 
intramolceular disulfide bond was formed by the ferricyanide prod- 
dare. The peptide having the intramolecular disulfide bond was puri- 
fied by preparative r verse-phase high performance liquid chromatog- 
raphy (HPLC) on a column of TSKgel ODS 120-T (21.5 mm i.d. × 300 
ram) (Tosoh, Tokyo, Japan) using a linear acetonitrile gradient (20- 
60% over 1 h) in 0.1% trifluoroaeetic a id at a flow rate of 10 ml/min. 
The purity of the peptide was confirmed by analytical reverse-phase 
HPLC and amino acid analysis. Fast atom bombardment mass spec- 
trometry and 600 M Hz ~H NMR indicated that he synthetic 1RL 1038 
did not contain polymers or a~regates. 
2.3. Membrane preparation 
Tissu~ ,'rat aorta, lung and cerebellum; guinea pig heart, lung, 
trachea, ileum and cerebellum; porcine aorta and lung; and human 
umbilical vein and placenta) were homogenized with 9 vols. of ice-cold 
0.25 M sucrose containing 20 mM Tris-HCl (pH 7.4), 0.2 mM phea- 
ylmethylsulfonyi fluoride, 1/,tM leupeptin, 1/zM pepstatin, 0.1 mM 
EDTA, and 0.5 mM EGTA in a Polytron homogenizer (Kinematica, 
Lucerne, Switzerland). The homogenate was centrifuged at 1,000 x g 
for 10 rain at 4°C, and the resultant supernatant was centrifuged again 
at 48,000 x g for 20 rain. The sedimented membranes were washed 
three times with the same buffer and stored in aliquots at -80°C until 
use, 
2.4. ET binding assays 
[~-'Sl]ET-1 was used as the ligand to assess binding to the ETA 
receptor in the presence of 1 nM unlabeled ET-3 to mask the ETa 
receptor, whereas the binding to the ET~ receptor was measured with 
[~ ~I]ET-3 as the ligand. The binding assay was performed as described 
previously [10]. In brief, the membranes (1-30/zg of protein) were 
incubated at 37°C for 1 h with [12Sl]ET-I or [~-'Sl]ET-3 in 20 mM 
HEPE$ (pH 7.4), 145 mM NaCl, 4 mM KCI, 1.2 mM M8Ci,., 1.0 mM 
EGTA, 0. i% bovine serum albumin, and 0.02% bacitracin (final vol. 
1.0 ml). The incubation was terminated by centrifugation f the mix- 
tare at 20,000 xg for 20 rain at 4°C. The membrane-associated radio- 
activity was then measured in a gamma counter. Specific binding was 
defined as total binding tnimts non-specific binding obtained in the 
presence of 100 nM unlabeled ET-1 or ET-3. Total binding was always 
<10% of the total radioactivity added. Protein was determined by 
using a BCA assay kit (Pierce). 
2.5. Covalent labeling of ET receptors 
Membranes were incubated with [t~Sl]ET-I as described above x- 
cept that bovine serum albumin and baeitraein were omitted from the 
buffer. After the incubation, 1mM DSS, a covalent cross-linking 
reagent, was added and incubation was carried out further at 250C for 
30 rain. The cross-linking reaction was then quenched by adding 100 
mM ammonium acetate. The membranes were recovered and washed 
by centrifagation, 5olttbili'zed in I% sodium dodecyl sulfate (SDS) by 
heating at 100°C for 5 min, and subjected to SDS-PAGE. After drying 
the gel, the radiolab,'led ET receptors were visualized with the aid of 
a Bioimage Analyzer BAS.2000 (Fuji Photo Film, Tokyo, Japan). 
2.6. Contraction as~'ays 
Rat aortic smooth muscle denuded of the endothelium, guinea pig 
trachea without he epithelium, and guinea pig ileal longitudinal mus- 
cle were excised and placed in an oxygenated (95% O:, 5% CO2) 
normal physiological salt solution (136.9 mM NaCl, 5.4 mM KCI, 1.5 
mM CaCl~., 1 mM MgCI.~, 23.8 mM NaHCOs, 0.0l mM EDTA, and 
5.5 mM glucose) at 37°C. The tissue v;c.s placed in a 20-ml organ bath 
containing the oxygenated salt ~olation. The contractile activity was 
measur~l isometrically via a strain gauge transducer (Nihon-goden, 
Tokyo, Jal~m), maintaining the preparation under a ,~"~ting ~'-,,~ion 
of 0.1 g for the aorta and trachea nd of 0.5 g for the ileum [11]. The 
high K + (65.4 raM) solution was made by substituting NaCI off0 mM 
with equimolar KCI and used to obtain acontrol value For contraction 
of each seglnent. Student's t-test was used for the statistical analysis 
of the results. 
3. RESULTS AND DISCUSSION 
The affinities of IRL 1038, ET-I, and ET-3 for the 
ETA and ETa receptors in membranes were assessed by 
measuring the inhibition of specific binding of [I-'51]ETs 
by the unlabeled ligands. Inhibition curves obtained for 
[~2SI]ET-3 binding to the ETa receptor in guinea pig ileal 
membranes and those for [I-'Sl]ET-1 binding to the ETA 
receptor in rat aortic membranes are shown in Fig. IA 
and B, respectively. Table I summarizes the apparent 
binding inhibition constant (Ki) values thus obtained for 
the two receptors in membranes from various mammal- 
inn tissues. As can be seen, iRL 1038 showed K~ values 
of 6-11 nM for the ETa receptor in the membranes 
tested. These values are 350- to 1,800-fold higher than 
those determined for the binding of ET-I and ET-3 to 
the same receptor (5-26 pM). On the other hand, the K~ 
values of IRL 1038 for the ETA receptor were 0.4-0.7 
/.tM, which are 7,000- to 15,000-fold higher than the Ki 
values of ET-I (30-96 pM) and about 20- to 60-fold 
higher than those of ET-3 (15-32 aM). These results 
indicate that IRL 1038 has a much higher affinity for 
the ETa receptor (Ki = 6-11 nM) than for the ET A 
receptor (K~ = 0.4-0.7/,tM), although the affinity of IRL 
1038 for the ETa receptor is considerably lower than 
that of ET-3. It can, therefore, be said that IRL 1038 
acts as a specific antagonist for the ETa receptor at a 
suitable concentration range. 
The selectivity of IRL 1038 to the ETa receptor was 
confirmed by cross-linking experiments. Guinea pig 
ileal and rat aortic membranes, which contain predom- 
inantly the ETa and ETA receptors, respectively, were 
incubated with 50 pM [~'Sl]ET-I and then cross-linked 
with DSS. Upon SDS-PAGE, the ileal membranes gave 
two radioactive bands of Mr 77,000 and 38,000 (Fig. 
2A). The Mr of the larger band coil~cides with that of 
the ETa receptor, whereas the smaller band seems to be 
a proteolytic product of the ETa receptor, as has been 
reported [12]. The radioactivity of both bands decreased 
to about 50% when incubated in the presence of 100 nM 
IRL 1038, and disappeared in the presence of l/.tM IRL 
1038. On the other hand, after the cross-linking, the 
ETA receptor in the aortic membranes was recovered as 
a radioactive band of Mr 77,000, but its intensity was 
almost unchanged when incubated in the presence of 1 
/~M IRL 1038 (Fig. 2B). 
As shown in Fig. 3, ET-3 as an agonist relatively 
specific for the ETa receptors induced dose-dependent 
contractions of rat aortic smooth muscle, guinea pig 
ileal longitudinal muscle, and guinea pig tracheal ring. 
Maximum responses were induced by 300 nM ET-3 in 
the ileum and trachea, which were about 4i% and 96% 
of those induced by the high K* solution, respectively. 
On the other hand, in the aorta, the muscle tension did 
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Fig. 1. Inhibition of binding of ['"q]ET.3 to the ETu receptor in guinea pig ileal membranes (A) and of [~"q]ET-I to the ETA receptor in rat aortic 
membranes (B) by unlabeled ET-I (o), ET-3 (~), and IRL 1038 (&). The ileal membrane (2/.tg protein) was incubated with 10 pM [~:Sl]ET-3 and 
the aortic membrane (30.ttg protein) with 40 pM [t:q]ET-1, ia the presence of various concentrations of unlabeled ligands as described in Materials 
and Methods. Each value is expressed as a percentage of the specific binding, 
not reach a maximum even at a concentration f 300 
nM ET-3. The ET-3 concentration i ducing half maxi- 
mal contraction (ECs0) was about 30 nM for both the 
ileum and trachea, The dose-response curve tbr the 
aorta was unaffected by the presence of 3 pM IRL 1038 
(Fig. 3A), even though the affinities of ET-3 and IRL 
1038 for the ETA receptor are not much different (K~ of 
IRL 1038/K, of ET-3 = 59). In contrast, even though the 
affinity of IRL 1038 for the ETa receptor is markedly 
lower than that of ET-3 (Ki of IRL 1038/K~ of ET.3 = 
1,100), the ET-3-induced contraction of the ileal and 
tracheal muscles was attenuated by 3/zM IRL 1038 
(Fig. 3B and C), the maximum tension being decreased 
by 52% and 38%, respectively. IRL 1038 at 3 aM did 
Table 1 
K~ values of ET-I, ET-3 and IRL 1038 on binding of [*"q]ETs to ETI) and ETA receptors in membranes of various mammalian tissues 
Species and tissucs Receptor K,t* (pM) B.,,,~* Kj values 
subtypes (fmol/mg prot.) 
ET-I (pM) ET-3 (pM) IRL 1038 (nM) 
Rat 
Lung ETz~ 19 3,700 26 18 9 
Cerebellum ETa 1 $ 1,700 17 11 6 
Aorta ETA 46 100 96 12,000 700 
Cuinea pig 
Lung ETa 16 2,300 I 0 10 11 
Trachea ET~ 11 3{50 8 8 9 
Ileum ETa 3 520 5 8 9 
Cerebellum ETa 5 340 11 11 1 I 
Heart ETA 28 860 41 32,000 630 
Pig 
Lung ET~ 8 360 8 10 10 
Aorta ETA 32 260 53 15,000 700 
Human 
PlacAnta ETa 12 490 12 11 9 
Umbilical vein ETA 37 370 30 16,000 430 
*The Re and B.,.~ )'or ET. receptors were determined with [;~q]ET-3, and tllose Ibr ETA receptors were with [tZ~ll~l'-l, in the presence of I nM 
unlabeled ET-3 to mask the bindin 8 sites for ET. receptors (also see Fig. l). 
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Fig. 2. Autoradiograms of SDS-PAGE of [t251]ET-I which was co- 
valently linked to the ET, receptor in guinea pig ileal membranes (A) 
and the ETa receptor in rat aortic membranes (B). The membranes 
were incubated with 50 pM [t-'~I]ET-I in the absence (lane I in A and 
B), or the presence of I0 nM (lane 2 in A), 100 nM (lane 3 in A), and 
1/aM (lane 4 in A and lane 2 in B) IRL 1038. Labeling of these bands 
was inhibited elTectivcly by an excess concentration (100 aM) of unla- 
beled ET-I (lane 5 in A and lane 3 i.~ B). The same bands were also 
observed tinder reducin~ conditions. The positions of t"~l.labeled 
marker proteins (DuPont New England Nuclear) and their M~ values 
in thousands are indicated on the left:/~-galaetosidase (M~= 116,000), 
bovine serum albumin (68,000), carbonic anhydrase (30,000), soybean 
trypsin inhibitor C20,100). 
not affect the contraction i duced by the high K ~ solu- 
tion in all the three tissues (data not shown), IRL 1038 
itself at 10tiM exerted little contractile effect in the three 
tissues, indicating that IRL 1038 has practically no ag- 
onistic activity in these tissues, 
Taken together, these results indicate that IRL 1038 
is an antagonist pecific for the ETa receptor in various 
mammalian tissues, and demonstrate hat contraction 
of guinea pig ileal and tracheal smooth muscle is, at 
least in part, mediated by the ETa receptor. 
Previously we synthesized a series of  linear peptides 
corresponding to the C-terminal portion of ET-1, and 
their N=-succinyl derivatives, and found that Suc- 
[Giu'~+Ala tl'ls]-ET-l(8-21) (termed IRL 1620) was the 
most potent and specific ligand for the ETa receptor 
[10]. Its K~ value for the ETa receptor in the porcine lung 
membranes is 16 pM and it is 60-fold more specific for 
the ETa receptor than ET-3 (the ratio of K i for ETA/K~ 
for ETa being 120,000 for IRL 1620 and 1,900 for ET- 
3). 1RL 1620 is actually an agonist and induces con- 
traction of guinea pig tracheal muscle with an efficiency 
comparable to that of ET.3 [10]. Since IRL 1620, but 
not IRL 1038, has a cluster of charged residues in the 
N-terminal portion, it seems that ~he cluster is involved 
in the agonist activity. The cluster also seems to contrib. 
ate to the high selectivity for the El'., receptor, in view 
of the fact that the selectivity ot" [RL 1038 to the ETa 
receptor (Ki for ETA/K~ for ETa = 50-120) is markedly 
lower than that of IRL 1620. Nevertheless it should be 
pointed out that IRL 1038, when used at appropriate 
concentrations, i  a specific antagonist for the ETa re- 
ceptor. When the disulfide bond of 1RL 1038 was re- 
moved by Cys-Ala substitution (IRL 1443 in [10]), the 
affinity and selectivity for the ETa receptor decreased 
markedly in porcine lung (K~ = 140 nM, K~ for ETA/K~ 
for ETa = 11) [10] and in various tissues of rats, guinea 
pigs, and humans (Ki = 800 nM-l .2/tM, K~ for ETA/K~ 
for ETa = 2-8), indicating that the disulfide bond in 
IRL 1038 is important to maintain its high affinity and 
selectivity for the ETa receptor. 
The ETa receptor was recently deduced to be signifi- 
cantly involved in positive inotropy [13], inflammation 
[14]. renal functions [15], asthma [16]. ocular functions 
[17], venous constriction [ 18], vasodilation [19] and also 
in several central nervous functions [20]. Thus, IRL 
1620 and IRL 1038, an ET, receptor-selective agonist 
and antagonist, respectively, will be useful to clarify the 
role of ETa-mediated responses in these biological func- 
tions. 
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i~ represented a~ a percentaBe of the contraction i duced by the high K + solution in each tissue, *Significantly different from the point in the absence 
of IRL 1038 with P<O,01, Each point r~presents the mean "+S.E.M, of 4 experiments, 
15 
Volume 31 1, j~umber I FEBS LETTERS October 1992 
b), Grants-in-aid lbr Scietatific Research l'rom the ~_inistry of Educa- 
tion, Science and Culture of }apart, 
REFERENCES 
[1] Yanagisawa, M., Kurihara, 1-1., t~'~ir0,ara. S., Tomoht~, '~.. 
Kobayashl, M., Mitsai. Y.. Yazaki, Y., Goto, K. and Masaki, T. 
(19881 Nature 332, 411-415. 
[2] Inoue, A., Yanagisawa. M., Kimura, S,, Kasuya, Y., Miyauchi, 
T., Goto, K. and Masaki, T, (19891 Proc. Natl. Acad. Sci, USA 
86, 2863-286% 
[31 Kloog, Y., Ambar, 1., Sokolovsky, M,, Kochva, E.~ Wollberg, Z, 
and Bdolah, A, (1988) Science 242, 268-270. 
[4] gubanyi, G.M. and Botelho, L.H.P. (19911 FASEB J. 5, 2713- 
2720. 
[5] Sak urai. T,, Yanagisawa, M. and Masaki, T. (19921 Trends Phar- 
ma¢ol. S¢i. 13, 103-108. 
[6] Ihara, M., Fukuroda, T,, Sae.ki, T., Nishikibe, M., Kojiri, K., 
Suda, H. and Yano, M. (19911 Bioehem, Biophys. Res, Commun. 
178, 132-137. 
[7] Miyata, S,, Hashinaoto, M,, Masui, Y., Ezaki, M., Takase, S., 
Nishlkaxva, M., Kiyoto, S., Okahara, M. and Kohsaka, M, (19921 
J, Antibiot. 45.74-82. 
[8] Fujimoto. M., Miyahara. S., Nakajima. S., Ueda, M., 
Nakanaura, M. and Sakurai, K. (19921 FEBS Left. 305, 41--44. 
[9] Spinelta, M., Malik. A.B.. Everitt, J. and Andersen, T.T. ( 19911 
Proc. Natl. Acad. Sci, USA 88, 7443-7446, 
[10] Takai. M,, Umemura, 1., Yamasaki, K., Watakabe, T ~ Fujitani, 
Y,, Oda, K., Urad¢, Y., Inui, T., Yamamura, T. and Okada, T, 
(19921 Bioehern. Biophys, ges, Commun, 184, 953-959, 
[11] Sakata, K., Ozaki, H,, Kwon, S.-C, and Karaki, H. (19891 Br, J, 
Pharma¢ol. 98, 483-492. 
[12] Kozuka, M., lto, T., Hirose, $., Lodhi, K.M. and Hagiwara, H. 
(19911 J, Biol. Chem. 266, 16892-16896. 
[I 3] Takanashi, M. ~.nd Endoh, M. (19911 Am. J. Physiol. 261, H611- 
H619. 
[14] Miyasaka, N., Hirata, Y., Ando, K., Sato, K,, Morita, FI., Sl~i- 
ehiri, M,, Kanno, K., Tomita, K. and Marumo, F, (19921 Arthri- 
tis Rheum. 35, 397--400. 
[15] Yamashita, Y,, Ytakimura, T,, Miura, K., Okumura, M, and 
Yamamoto, K. (19911 L Pharmaeol. Exp. Ther. 259, 1256-1260. 
[16] Candenas, M., Naline, E., Sarria, B. and Advenier, C. (1992) Ear. 
J. Pharmacol. 210, 291-297. 
[17] NlacCumber, M.W., .lampd, H.D. and Snyder, S.H. (19911 Arch. 
Ophthalmol, 109, 705-709. 
[18] Moreland, S,, McMullen, D,M., Delaney, C.L., Lee, V.G, and 
Hunt, J,T, (19921 Biochem. Biophys. R~s, Commun. 184, 100- 
106. 
[19] Fujitani, Y., Oda, K. Tak~moto, M., lnui, T., Okada, T. and 
Urade, Y. (19921 FEBS Lett. 298, 79-83, 
[20] Grecnberg, D.A., Chan, J. and Sainpson, H.A. (19921 NeurolosY 
42, 25-31. 
16 
